NanoVibronix (NASDAQ:NAOV) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Insider and Institutional Ownership

13.7% of NanoVibronix shares are owned by institutional investors. Comparatively, 23.1% of Establishment Labs shares are owned by institutional investors. 18.7% of NanoVibronix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.


This table compares NanoVibronix and Establishment Labs’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NanoVibronix -1,380.78% -180.81% -127.54%
Establishment Labs -34.47% -90.07% -35.01%

Analyst Recommendations

This is a summary of recent recommendations and price targets for NanoVibronix and Establishment Labs, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NanoVibronix 0 0 1 0 3.00
Establishment Labs 0 0 3 0 3.00

Establishment Labs has a consensus price target of $36.67, indicating a potential upside of 57.17%. Given Establishment Labs’ higher probable upside, analysts clearly believe Establishment Labs is more favorable than NanoVibronix.

Valuation & Earnings

This table compares NanoVibronix and Establishment Labs’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NanoVibronix $320,000.00 48.83 -$4.96 million ($1.17) -3.27
Establishment Labs $61.21 million 7.77 -$21.10 million ($1.12) -20.83

NanoVibronix has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than NanoVibronix, indicating that it is currently the more affordable of the two stocks.


Establishment Labs beats NanoVibronix on 8 of the 12 factors compared between the two stocks.

NanoVibronix Company Profile

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.

Establishment Labs Company Profile

Establishment Labs Holdings Inc., a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue. The company sells its products through exclusive distributors and direct sales force in 60 countries worldwide. Establishment Labs Holdings Inc. was founded in 2004 and is headquartered in Alajuela, Costa Rica.

Receive News & Ratings for NanoVibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoVibronix and related companies with's FREE daily email newsletter.